Bivalent mRNA-1273.214 Elicits Better Response Against Omicron

TUESDAY, Sept. 27, 2022 (HealthDay News) -- Interim results of an ongoing study show that use of the bivalent omicron-containing vaccine mRNA-1273.214 as a second booster elicits neutralizing antibody responses against omicron that are superior to those for mRNA-1273, according to a study published online Sept. 16 in the New England Journal of Medicine.
Spyros Chalkias, M.D., from Moderna in Cambridge, Massachusetts, and colleagues compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster in an ongoing phase 2 to 3 study. mRNA-1273.214 or mRNA-1273 was administered as a booster to adults who had previously received a two-dose primary series and first booster dose of mRNA-1273 three or more months earlier (437 and 377 participants, respectively).
The researchers found that for participants with no previous severe acute respiratory syndrome coronavirus 2 infection, the geometric mean titers of neutralizing antibodies against the omicron BA.1 variant were 2,372.4 and 1,473.5 after receipt of the mRNA-1273.214 and mRNA-1273 boosters, respectively. In addition, the mRNA-1273.214 and mRNA-1273 boosters elicited geometric mean titers of 727.4 and 492.1, respectively, against omicron BA.4 and BA.5; higher binding antibody responses against multiple other variants was elicited by the mRNA-1273.214 booster versus the mRNA-1273 booster. The two boosters had similar safety and reactogenicity.
"These results are consistent with the evaluation of our bivalent beta-containing vaccine, which induced enhanced and durable antibody responses," the authors write. "Together, these findings indicate that bivalent vaccines may be a new tool in the response to emerging variants."
Several authors disclosed financial ties to pharmaceutical companies, including Moderna, which funded the study.
Related Posts
Breast Cancer Survivors Can Safely Interrupt Therapy During Pregnancy: Study
WEDNESDAY, May 3, 2023 (HealthDay News) -- For young women who survive breast...
Vapear podría ser malo para la vida sexual de los hombres
MIÉRCOLES, 1 de diciembre de 2021 (HealthDay News) -- Vapear puede ser malo para...
Oral Surgery on Your Calendar? Expert Offers Tips to Ease Anxiety
SUNDAY, Sept. 4, 2022 (HealthDay News) -- If you’re planning to have oral...
Moderate-to-Severe Psoriasis Tied to Lower Fertility Rates in Women
WEDNESDAY, June 21, 2023 (HealthDay News) -- Patients with moderate-to-severe...